The Research Institute in Miami conducts a clinical study to evaluate the effects of fatty acids on omega-3 and vitamin D of the progress of type 1 diabetes. The group of patients will be 56 adults and children.
A pilot study of high doses of Omega-3 and Vitamin D in T1D (POSEIDON) is being conducted by the Diabetes Research Institute at Miami Miller’s School of Medicine. Its primary goal is to prove that the use of high doses of omega-3 and vitamin D may suppress the development of type 1 diabetes.
The theory of researchers relies on the quality of both substances to protect insulin-producing cells.
“The role of Omega-3 / Vitamin D in maintaining beta-cell function in children with type 1 diabetes requires additional research,” said Dr. Camillo Ricardo, sponsor of the POSEIDON study.
In POSEIDON, 56 adults and children with diabetes will be involved. People who have recently been diagnosed with diabetes and those with an illness for more than six months are allowed to participate. Due to this variation, researchers will be able to evaluate the effects of the early and late intervention.
For one year, patients will receive vitamin D separately or in combination with omega-3 fatty acids. In this case, treatment with insulin will be continued, and over the diet of participants in the program, researchers will establish the control. After the expiry of the deadlines, the patients are expected the year of medical observation.
During the observation period, researchers will measure long-term effects on blood sugar levels and will observe any other insulin jumps in indicators.
According to Dr. Camillo Ricardo, if the combination of Omega-3 and vitamin D can delay the progression or end of autoimmunity in type 1 diabetes, it is expected that this will lead to the preservation of insulin secretion, minimal usage of exogenous insulin and metabolism improvement that will minimize the risks associated with an unstable blood glucose level. ”
Dr. Ricardo also hopes that if the results are confident they can be used not only to help people with type 1 diabetes but also to help patients with other autoimmune diseases.
“A reversible autoimmunity can be useful not only within Type 1 diabetes. The use of similar strategies should be tested for the treatment of other autoimmune diseases, such as rheumatoid arthritis and erythematous lupus, “- commented Dr. Rikordy.